Table II.
Chemotherapy regimens and timing.
| Chemotherapy (n = 556) | No chemotherapy (n = 2121) | All cases (n = 2677) | |
|---|---|---|---|
| Chemotherapy, intravenous, n (%) | |||
| No Docetaxel + no other intravenous chemotherapy | 66 (11.9) | 2121 (100.0) | 2187 (81.7) |
| Docetaxel + no other chemotherapy | 395 (71.0) | 395 (14.8) | |
| Docetaxel + mitoxantrone | 46 (8.3) | 46 (1.7) | |
| Docetaxel + other chemotherapy | 20 (3.6) | 20 (0.7) | |
| No Docetaxel + mitoxantrone | 4 (0.7) | 4 (0.1) | |
| No Docetaxel+ other chemotherapy | 25 (4.5) | 25 (0.9) | |
| Chemotherapy, peroral, n (%) | |||
| KEES | 35 (6.3) | 35 (1.3) | |
| Cyklophosphamide | 50 (9.0) | 50 (1.9) | |
| Estramustine | 41 (7.4) | 41 (1.5) | |
| Mixture/other | 11 (2.0) | 11 (0.4) | |
| No peroral chemotherapy | 419 (75.4) | 2121 (100.0) | 2540 (94.9) |
| Prednisone, n (%) | |||
| Yes | 407 (73.2) | 510 (24.0) | 917 (34.3) |
| No | 149 (26.8) | 1611 (76.0) | 1760 (65.7) |
| Time of last dose of chemotherapy | |||
| Peroral chemotherapy | 66 (11.9) | 2121 (100.0) | 2187 (81.7) |
| Last chemo 0–1 month prior to death | 45 (8.1) | 45 (1.7) | |
| Last chemo 1–2 month prior to death | 60 (10.8) | 60 (2.2) | |
| Last chemo 2–6 months prior to death | 178 (32.0) | 178 (6.6) | |
| Last chemo 6–12 months prior to death | 128 (23.0) | 128 (4.8) | |
| Last chemo 1 + years prior to death | 79 (14.2) | 79 (3.0) |
KEES, ketokonazole, estramustine, etoposide, sendoxan/cyclophosphamide [17].